» Articles » PMID: 38782973

Characterizing the Human Intestinal Chondroitin Sulfate Glycosaminoglycan Sulfation Signature in Inflammatory Bowel Disease

Abstract

The intestinal extracellular matrix (ECM) helps maintain appropriate tissue barrier function and regulate host-microbial interactions. Chondroitin sulfate- and dermatan sulfate-glycosaminoglycans (CS/DS-GAGs) are integral components of the intestinal ECM, and alterations in CS/DS-GAGs have been shown to significantly influence biological functions. Although pathologic ECM remodeling is implicated in inflammatory bowel disease (IBD), it is unknown whether changes in the intestinal CS/DS-GAG composition are also linked to IBD in humans. Our aim was to characterize changes in the intestinal ECM CS/DS-GAG composition in intestinal biopsy samples from patients with IBD using mass spectrometry. We characterized intestinal CS/DS-GAGs in 69 pediatric and young adult patients (n = 13 control, n = 32 active IBD, n = 24 IBD in remission) and 6 adult patients. Here, we report that patients with active IBD exhibit a significant decrease in the relative abundance of CS/DS isomers associated with matrix stability (CS-A and DS) compared to controls, while isomers implicated in matrix instability and inflammation (CS-C and CS-E) were significantly increased. This imbalance of intestinal CS/DS isomers was restored among patients in clinical remission. Moreover, the abundance of pro-stabilizing CS/DS isomers negatively correlated with clinical disease activity scores, whereas both pro-inflammatory CS-C and CS-E content positively correlated with disease activity scores. Thus, pediatric patients with active IBD exhibited increased pro-inflammatory and decreased pro-stabilizing CS/DS isomer composition, and future studies are needed to determine whether changes in the CS/DS-GAG composition play a pathogenic role in IBD.

Citing Articles

Chondroitin Sulfate Nanovectorized by LC-PUFAs Nanocarriers Extracted from Salmon () by Green Process with Decreased Inflammatory Marker Expression in Interleukin-1β-Stimulated Primary Human Chondrocytes In Vitro Culture.

Pruvost L, Gerlei M, Paris C, Velot E, Kahn C, Bianchi A Mar Drugs. 2024; 22(12).

PMID: 39728145 PMC: 11676681. DOI: 10.3390/md22120571.


Characterising glycosaminoglycans in human breastmilk and their potential role in infant health.

Greenwood M, Murciano-Martinez P, Berrington J, Flitsch S, Austin S, Stewart C Microb Cell. 2024; 11:221-234.

PMID: 38975022 PMC: 11224681. DOI: 10.15698/mic2024.07.827.

References
1.
Hori Y, Hoshino J, Yamazaki C, Sekiguchi T, Miyauchi S, Horie K . Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn J Pharmacol. 2001; 85(2):155-60. DOI: 10.1254/jjp.85.155. View

2.
Yang E, Panaccione N, Whitmire N, Dulai P, Vande Casteele N, Singh S . Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020; 51(11):1031-1038. PMC: 8032452. DOI: 10.1111/apt.15719. View

3.
Allaire J, Crowley S, Law H, Chang S, Ko H, Vallance B . The Intestinal Epithelium: Central Coordinator of Mucosal Immunity. Trends Immunol. 2018; 39(9):677-696. DOI: 10.1016/j.it.2018.04.002. View

4.
Petrey A, de la Motte C . The extracellular matrix in IBD: a dynamic mediator of inflammation. Curr Opin Gastroenterol. 2017; 33(4):234-238. PMC: 5562400. DOI: 10.1097/MOG.0000000000000368. View

5.
Chalkidi N, Paraskeva C, Koliaraki V . Fibroblasts in intestinal homeostasis, damage, and repair. Front Immunol. 2022; 13:924866. PMC: 9399414. DOI: 10.3389/fimmu.2022.924866. View